Skip to main content

Table 3 Comparison of the characteristics and prognoses of histological grade II–IV spinal cord glioma patients with or without the H3 K27M mutation

From: The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation

 

Histological Grade II

Histological Grade III

Histological Grade IV

H3 wildtype

H3 K27M-mutant

P-value

H3 wildtype

H3 K27M-mutant

P-value

H3 wildtype

H3 K27M-mutant

P-value

Number

37

14

 

6

14

 

5

7

 

Age (year)

29

36

n.s

30

35

n.s

51

20

0.0101

 

(6–54)

(10–51)

 

(13–63)

(9–52)

 

(30–63)

(13–36)

 

Gender

  

n.s

  

n.s

  

n.s

male

25(68%)

7(50%)

 

4(67%)

9(64%)

 

2(40%)

2(29%)

 

female

12(32%)

7(50%)

 

2(33%)

5(36%)

 

3(60%)

5(71%)

 

Location

  

n.s

  

n.s

  

n.s

C

16(43%)

5(36%)

 

1(17%)

3(21%)

 

2(40%)

2(29%)

 

C-T

5(14%)

1(7%)

 

0(0%)

3(21%)

 

1(20%)

3(43%)

 

T

13(35%)

7(50%)

 

4(67%)

6(43%)

 

2(40%)

2(29%)

 

T-L

3(8%)

1(7%)

 

1(17%)

2(14%)

 

0(0%)

0

 

Resection

  

< 0.0001

  

n.s

  

n.s

GTR

30(81%)

3(21%)

 

5(83%)

7(50%)

 

3(60%)

2(29%)

 

STR

3(8%)

3(21%)

 

1(17%)

3(21%)

 

2(40%)

4(57%)

 

OB

4(11%)

8(57%)

 

0(0%)

4(29%)

 

0(0%)

1(14%)

 

Radio

  

n.s

  

n.s

  

n.s

yes

25(68%)

9(64%)

 

4(67%)

10(71%)

 

1(20%)

4(57%)

 

no

8(22%)

3(21%)

 

1(17%)

3(21%)

 

3(60%)

0(0%)

 

unknown

4(11%)

2(14%)

 

1(17%)

1(7%)

 

1(20%)

3(43%)

 

Chemo

  

n.s

  

n.s

  

n.s

yes

6(16%)

4(29%)

 

3(50%)

7(50%)

 

1(20%)

2(29%)

 

no

27(73%)

8(57%)

 

2(33%)

5(36%)

 

3(60%)

2(29%)

 

unknown

4(11%)

2(14%)

 

1(17%)

2(14%)

 

1(20%)

3(43%)

 

IDH1

  

n.s

  

n.s

  

n.s

wildtype

26(70%)

11(79%)

 

4(67%)

10(71%)

 

3(60%)

4(57%)

 

mutant

0(0%)

0(0%)

 

0(0%)

0(0%)

 

0(0%)

0(0%)

 

unknown

11(30%)

3(21%)

 

2(33%)

4(29%)

 

2(40%)

3(43%)

 

TERT promoter

  

n.s

  

n.s

  

n.s

wildtype

17(46%)

10(71%)

 

4(67%)

8(57%)

 

3(60%)

3(43%)

 

mutant

9(24%)

1(7%)

 

0(0%)

2(14%)

 

0(0%)

1(14%)

 

unknown

11(30%)

3(21%)

 

2(33%)

4(29%)

 

2(40%)

3(43%)

 

BRAF V600E

  

n.s

  

0.0020

  

n.s

wildtype

23(62%)

10(71%)

 

1(17%)

10(71%)

 

2(40%)

4(57%)

 

mutant

3(8%)

0(0%)

 

3(50%)

0(0%)

 

1(20%)

0(0%)

 

unknown

11(30%)

4(29%)

 

2(33%)

4(29%)

 

2(40%)

3(43%)

 

Ki-67

  

0.0108

  

n.s

  

n.s

< 10%

28(76%)

6(43%)

 

2(33%)

1(7%)

 

0(0%)

0(0%)

 

≥10%

7(19%)

8(57%)

 

4(67%)

13(93%)

 

5(100%)

7(100%)

 

unknown

2(5%)

0(0%)

 

0(0%)

0(0%)

 

0(0%)

0(0%)

 

Median OS (months)

Und

24.23

< 0.0001

Und

24.47

n.s

10.83

12.10

n.s

  1. C cervical vertebrae, C-T cervicothoracic vertebrae, T thoracic vertebrae, T-L thoracolumbar vertebrae, GTR gross total resection, STR subtotal resection, OB open biopsy, Radio Radiotherapy, Chemo Chemotherapy
  2. Significant P-values are indicated in bold text